- Home
- GLBE vs NUVL Comparison
GLBE vs NUVL Comparison
Compare GLBE & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBE
- NUVL
- Stock Information
- Founded
- GLBE 2013
- NUVL 2017
- Country
- GLBE Israel
- NUVL United States
- Employees
- GLBE N/A
- NUVL N/A
- Industry
- GLBE Computer Software: Prepackaged Software
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- GLBE Technology
- NUVL Health Care
- Exchange
- GLBE Nasdaq
- NUVL Nasdaq
- Market Cap
- GLBE 6.0B
- NUVL 7.1B
- IPO Year
- GLBE 2021
- NUVL 2021
- Fundamental
- Price
- GLBE $35.12
- NUVL $109.19
- Analyst Decision
- GLBE Buy
- NUVL Strong Buy
- Analyst Count
- GLBE 13
- NUVL 13
- Target Price
- GLBE $48.62
- NUVL $133.85
- AVG Volume (30 Days)
- GLBE 1.6M
- NUVL 734.4K
- Earning Date
- GLBE 11-19-2025
- NUVL 10-30-2025
- Dividend Yield
- GLBE N/A
- NUVL N/A
- EPS Growth
- GLBE N/A
- NUVL N/A
- EPS
- GLBE 0.04
- NUVL N/A
- Revenue
- GLBE $888,450,000.00
- NUVL N/A
- Revenue This Year
- GLBE $28.17
- NUVL N/A
- Revenue Next Year
- GLBE $24.07
- NUVL N/A
- P/E Ratio
- GLBE $898.70
- NUVL N/A
- Revenue Growth
- GLBE 31.57
- NUVL N/A
- 52 Week Low
- GLBE $26.64
- NUVL $55.54
- 52 Week High
- GLBE $63.69
- NUVL $112.88
- Technical
- Relative Strength Index (RSI)
- GLBE 46.53
- NUVL 66.08
- Support Level
- GLBE $33.54
- NUVL $93.05
- Resistance Level
- GLBE $37.40
- NUVL $112.53
- Average True Range (ATR)
- GLBE 1.58
- NUVL 5.84
- MACD
- GLBE -0.12
- NUVL 1.06
- Stochastic Oscillator
- GLBE 36.81
- NUVL 84.34
About GLBE Global-E Online Ltd.
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from and anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.